Pyrotechnic initiator

Precision Oncology Innovator SimBioSys and General Inception Announce Strategic Partnership to Accelerate Cancer Drug Development

Retrieved on: 
Wednesday, April 3, 2024
Oncology, Health, Other Health, Research, Science, Pharmaceutical, Biotechnology, Pyrotechnic initiator, Partnership, Patient, Neoplasm, Biomarker, GI, Credentialing, Cancer, AI, Clinical trial, Drug development, Therapy, Pharmaceutical industry

SimBioSys, a leading innovator in precision oncology, and General Inception (“GI”), a global company Igniter, today announced a strategic partnership that aims to significantly reduce oncology drug development times and cut development costs by using AI and biophysical modeling to better understand unique tumor spatial biophysical characteristics.

Key Points: 
  • SimBioSys, a leading innovator in precision oncology, and General Inception (“GI”), a global company Igniter, today announced a strategic partnership that aims to significantly reduce oncology drug development times and cut development costs by using AI and biophysical modeling to better understand unique tumor spatial biophysical characteristics.
  • The level of drug development in oncology is intense, with more than 2,000 products currently under development and drug trial starts up 22% in 2022 compared to 2018.
  • By partnering with General Inception, we can cut their oncology drug development time and costs significantly.
  • This strategic relationship not only underscores our commitment to innovation in the fight against cancer but also promises to deliver groundbreaking precision oncology drugs to patients faster than ever before.”

Precision Oncology Innovator SimBioSys and General Inception Announce Strategic Partnership to Accelerate Cancer Drug Development

Retrieved on: 
Wednesday, April 3, 2024
Pyrotechnic initiator, Partnership, Patient, Neoplasm, Biomarker, Credentialing, Cancer, AI, Drug development, PALO, Clinical trial, Therapy, Simbiosys, Pharmaceutical industry

CHICAGO & PALO ALTO, Calif., April 3, 2024 /PRNewswire/ -- SimBioSys, a leading innovator in precision oncology, and General Inception ("GI"), a global company Igniter, today announce a strategic partnership that aims to significantly reduce oncology drug development times and cut development costs by using AI and biophysical modeling to better understand unique tumor spatial biophysical characteristics.

Key Points: 
  • Drug development in oncology is at high levels, with more than 2,000 products currently under development and drug trial starts up 22% in 2022 from 2018.
  • [1]
    Venkat Reddy, Chief Scientific Officer of General Inception, said: "This collaboration marks a significant milestone in the pursuit of more effective, personalized cancer therapies, as all new oncology drug incubations under General Inception will be able to use SimBioSys' state-of-the-art PhenoScope platform and drug development services.
  • Tushar Pandey, Chief Executive Officer of SimBioSys, said: "Together, we are committed to introducing much-needed precision to the drug development process.
  • By partnering with General Inception, we can cut their oncology drug development time and costs significantly.

Precision Oncology Innovator SimBioSys and General Inception Announce Strategic Partnership to Accelerate Cancer Drug Development

Retrieved on: 
Wednesday, April 3, 2024
Pyrotechnic initiator, Partnership, Patient, Neoplasm, Biomarker, Credentialing, Cancer, AI, Drug development, PALO, Clinical trial, Therapy, Simbiosys, Pharmaceutical industry

CHICAGO & PALO ALTO, Calif., April 3, 2024 /PRNewswire/ -- SimBioSys, a leading innovator in precision oncology, and General Inception ("GI"), a global company Igniter, today announce a strategic partnership that aims to significantly reduce oncology drug development times and cut development costs by using AI and biophysical modeling to better understand unique tumor spatial biophysical characteristics.

Key Points: 
  • Drug development in oncology is at high levels, with more than 2,000 products currently under development and drug trial starts up 22% in 2022 from 2018.
  • [1]
    Venkat Reddy, Chief Scientific Officer of General Inception, said: "This collaboration marks a significant milestone in the pursuit of more effective, personalized cancer therapies, as all new oncology drug incubations under General Inception will be able to use SimBioSys' state-of-the-art PhenoScope platform and drug development services.
  • Tushar Pandey, Chief Executive Officer of SimBioSys, said: "Together, we are committed to introducing much-needed precision to the drug development process.
  • By partnering with General Inception, we can cut their oncology drug development time and costs significantly.

General Inception Celebrates Its First Anniversary with Over 35 Companies

Retrieved on: 
Thursday, October 5, 2023
Research, Technology, Software, General Health, University, Health, Data Management, Science, Education, Other Science, GI, Family, UCLA, Incubator, Entrepreneurship, VCS, Entrepreneur (magazine), Life, Pyrotechnic initiator, Cryptocurrency

General Inception (GI) , the first company Igniter, today celebrated its one-year anniversary of co-founding category-defining companies by setting a solid foundation in company formation to nurture and scale innovation for the long term.

Key Points: 
  • General Inception (GI) , the first company Igniter, today celebrated its one-year anniversary of co-founding category-defining companies by setting a solid foundation in company formation to nurture and scale innovation for the long term.
  • The GI model centers on bringing the right people together at the right time for successful company formation, business planning and market entry execution.
  • We have been scientists, operators, entrepreneurs, and investors, so we know this journey,” said Paul Connley, Co-Founder and CEO of General Inception.
  • For more information on General Inception and the world-changing companies it is co-founding, please visit www.generalinception.com .

General Inception Announces Strategic Partnership With SATT Paris-Saclay to Ignite Company Formation With Renowned French Research Laboratories

Retrieved on: 
Monday, December 5, 2022
Start-Up, Data Management, Biotechnology, Technology, Professional Services, Health, Business, Health Technology, Other Technology, Research, Science, Transfer, Laboratory, GI, CNRS, Polytechnic Institute of Paris, Investment, IP, Partnership, Pyrotechnic initiator, Research, Government, Paris-Saclay University, Technology transfer, Industrial design, Renewable energy

With SATT Paris-Saclay, General Inception is forming a valued partnership with one of the largest research coalitions in Western Europe.

Key Points: 
  • With SATT Paris-Saclay, General Inception is forming a valued partnership with one of the largest research coalitions in Western Europe.
  • General Inception will work closely with specialists of technology transfer and leading academic and research institutions.
  • The technical and intellectual property expertises of the SATT team will enable the review of hundreds of innovations each year.
  • General Inception will perform market analysis and product development as well as leverage its global capabilities to accelerate company formation and market entry, including in the USA.

General Inception Creates First-Ever “Igniter” for New Company Formation

Retrieved on: 
Thursday, September 29, 2022
Robotics, Data Management, IOT (Internet of Things), Technology, Metaverse, Artificial Intelligence, Digital Cash Management, Digital Assets, Risk, Organization, GI, Intellectual property, Mercury, Foundation, Invention, VC, Decision-making, CEO, Stanford University, Stanford University School of Medicine, Pyrotechnic initiator, Science, Inception, Multimedia, Fine chemical, Management, Cryptocurrency

General Inception (GI), the first-ever Igniter, today announced its launch to build deep-tech companies from their inception through commercial scale-up.

Key Points: 
  • General Inception (GI), the first-ever Igniter, today announced its launch to build deep-tech companies from their inception through commercial scale-up.
  • View the full release here: https://www.businesswire.com/news/home/20220929005467/en/
    General Inception is creating a new category of company formation.
  • General Inception comes in from day one with an experienced team to ensure strategic company inception and development.
  • General Inception is pioneering company creation as the first Igniter company.